PMID- 36002855
OWN - NLM
STAT- MEDLINE
DCOM- 20220826
LR  - 20221207
IS  - 1476-511X (Electronic)
IS  - 1476-511X (Linking)
VI  - 21
IP  - 1
DP  - 2022 Aug 25
TI  - Prevalence of dyslipidemia, treatment rate and its control among patients with 
      type 2 diabetes mellitus in Northwest China: a cross-sectional study.
PG  - 77
LID - 10.1186/s12944-022-01691-1 [doi]
LID - 77
AB  - BACKGROUND: The prevalence of cardiovascular disease (CVD) is high in China, 
      especially in Northwest China, and dyslipidemia in diabetes is a major factor at 
      risk for CVD. The dyslipidemia prevalence, treatment and control among type 2 
      diabetes mellitus (T2DM) patients in Northwest China were investigated. METHODS: 
      In the cross-sectional retrospective research, 1386 medical records of T2DM 
      patients were collected from the Endocrine Department of Tangdu Hospital. And 
      patients' age, sex, diabetes duration, glycated hemoglobin (HbA1c), 
      complications, lipid levels, and drug use were recorded. The patient 
      characteristics, lipid level and lipid-lowering therapy were analyzed. RESULTS: 
      In this study, the dyslipidemia prevalence among T2DM patients was 87.7%, the 
      treatment rate was 68.0%. The overall control rate of low-density lipoprotein 
      cholesterol (LDL-C) was 43.1%, and control rates reached 52.7% for high-risk 
      subjects and 36.1% for very high-risk subjects. The overall control rate of 
      non-high-density lipoprotein cholesterol (non-HDL-C) was 19.8%. HbA1c (%) >/= 7 was 
      indicated as a major factor predicting failure of LDL-C and non-HDL-C control 
      [odds ratio (OR) 1.521; 2.206, 95% confidence interval (CI) 1.154-2.005; 
      1.583-3.076)]. CONCLUSION: Among patients with T2DM, it is high prevalence of 
      dyslipidemia and low rate of treatment and control, and higher HbA1c level is the 
      main factor for poor lipid control. It calls for more efforts to promote early 
      screening, prevention and treatment of dyslipidemia for patients, thereby 
      reducing the risk of CVD.
CI  - (c) 2022. The Author(s).
FAU - Li, Jiahang
AU  - Li J
AD  - Department of Pharmacy, The Second Affiliated Hospital of Air Force Medical 
      University, Xi'an 710038, China.
FAU - Nie, Zhenxing
AU  - Nie Z
AD  - Department of Pharmacy, The Second Affiliated Hospital of Air Force Medical 
      University, Xi'an 710038, China.
AD  - Department of Pharmacy, Hanzhong Municipal People's Hospital, Hanzhong, 723000, 
      China.
FAU - Ge, Zhongli
AU  - Ge Z
AD  - Department of Pharmacy, The Second Affiliated Hospital of Air Force Medical 
      University, Xi'an 710038, China.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Pharmacy, The Second Affiliated Hospital of Air Force Medical 
      University, Xi'an 710038, China.
FAU - Gao, Bin
AU  - Gao B
AD  - Department of Endocrinology, The Second Affiliated Hospital of Air Force Medical 
      University, Xi'an 710038, China. bingao0726@163.com.
FAU - Yang, Yan
AU  - Yang Y
AD  - Department of Pharmacy, The Second Affiliated Hospital of Air Force Medical 
      University, Xi'an 710038, China. yangyan123@fmmu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20220825
PL  - England
TA  - Lipids Health Dis
JT  - Lipids in health and disease
JID - 101147696
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Glycated Hemoglobin A)
SB  - IM
MH  - *Cardiovascular Diseases/complications/epidemiology/prevention & control
MH  - China/epidemiology
MH  - Cholesterol, LDL
MH  - Cross-Sectional Studies
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Dyslipidemias/diagnosis/drug therapy/epidemiology
MH  - Glycated Hemoglobin
MH  - Humans
MH  - Prevalence
MH  - Retrospective Studies
MH  - Risk Factors
PMC - PMC9404639
OTO - NOTNLM
OT  - Control
OT  - Dyslipidemia
OT  - Prevalence
OT  - Treatment
OT  - Type 2 diabetes mellitus
COIS- The authors declare no competing interests.
EDAT- 2022/08/25 06:00
MHDA- 2022/08/27 06:00
PMCR- 2022/08/25
CRDT- 2022/08/24 23:38
PHST- 2022/06/10 00:00 [received]
PHST- 2022/08/18 00:00 [accepted]
PHST- 2022/08/24 23:38 [entrez]
PHST- 2022/08/25 06:00 [pubmed]
PHST- 2022/08/27 06:00 [medline]
PHST- 2022/08/25 00:00 [pmc-release]
AID - 10.1186/s12944-022-01691-1 [pii]
AID - 1691 [pii]
AID - 10.1186/s12944-022-01691-1 [doi]
PST - epublish
SO  - Lipids Health Dis. 2022 Aug 25;21(1):77. doi: 10.1186/s12944-022-01691-1.